Matthew Link has sold stock and made no open-market buys since Dec 2016

Matthew “Matt” Link is a healthcare and medical technology executive who has served as Chief Commercial Officer (CCO) of Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on innovative treatments for glaucoma and dry eye disease.( Appointed CCO effective September 11, 2023, Link led global commercial strategy and growth initiatives for Sight Sciences’ portfolio of interventional technologies targeting diseases of the anterior segment of the eye.( He is a corporate insider at Sight Sciences by virtue of this executive role and related equity holdings.(

Link has more than 20 years of experience building commercial teams and driving innovation in healthcare and medtech, including nearly 15 years in regional and executive leadership roles at NuVasive, Inc., where he advanced from Area Business Manager to President, overseeing global business units in spine, neurophysiology, and orthopedics and helping grow revenue from under $100 million to over $1 billion.( Prior to NuVasive, he held commercial leadership positions at Depuy Orthopedics and Depuy Spine, and has also served as Managing Partner at Orion Healthcare Advisors LLC, advising medtech businesses on strategy and commercialization.( Outside his executive posts, Link serves on the boards of Springbok Analytics, Fibrobiologics, and DinamicOR, and has served on the oversight board of the Coulter Translational Research Endowment at the University of Virginia.( He holds a BSEd in Physical Education and Sports Medicine from the University of Virginia, providing a foundation in human performance and injury management that underpins his career in orthopedic and eyecare technologies.(

Written by Perplexity from public sources.